On September 26, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain (Press release, BeiGene, SEP 26, 2019, View Source [SID1234539857]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Title: Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presentation #: 483P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

Title: Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presentation #: 482P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

Title: Updated Results of the PARP1/2 Inhibitor Pamiparib in Combination with Low-dose Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors
Presentation #: 451PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Agostina Stradella, M.D., Catalan Institute of Oncology, Spain

Title: Safety, Antitumor Activity, and Pharmacokinetics of Pamiparib, a PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors: Updated Phase 1 Dose-Escalation/Expansion Results
Presentation #: 452PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Mark Voskoboynik, MBBS, FRACP, Nucleus Network, Australia

Title: First Report of Efficacy and Safety from a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma in Asian Patients
Presentation #: 920P
Date: Monday, September 30
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Dingwei Ye, M.D., Ph.D., Fudan University Cancer Institute, China